Several other research analysts also recently commented on the company. National Securities restated a buy rating and set a $15.00 price objective on shares of Arcadia Biosciences in a report on Thursday, May 9th. HC Wainwright restated a buy rating and set a $14.00 price objective (down from $20.00) on shares of Arcadia Biosciences in a report on Thursday, June 6th.
Shares of NASDAQ RKDA remained flat at $$2.02 during midday trading on Thursday. The stock had a trading volume of 103,332 shares, compared to its average volume of 122,257. The company has a quick ratio of 6.19, a current ratio of 6.26 and a debt-to-equity ratio of 2.80. The company has a 50-day simple moving average of $3.10. Arcadia Biosciences has a 12-month low of $1.90 and a 12-month high of $10.40. The company has a market cap of $12.66 million, a price-to-earnings ratio of -0.38 and a beta of -2.01.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
See Also: Golden Cross
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.